Recruiting
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: cisplatin, Drug: docetaxel, Drug: gemcitabine hydrochloride, Drug: pemetrexed disodium, Drug: vinorelbine tartrate
Phase: Phase III
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: cisplatin, Drug: docetaxel, Drug: gemcitabine hydrochloride, Drug: pemetrexed disodium, Drug: vinorelbine tartrate
Phase: Phase III
Recruiting
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
Conditions: Lung Cancer
Interventions: Drug: sunitinib malate, Other: placebo
Phase: Phase III
Conditions: Lung Cancer
Interventions: Drug: sunitinib malate, Other: placebo
Phase: Phase III
Recruiting
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed, Drug: Pemetrexed, Drug: Paclitaxel, Drug: Carboplatin, Biological: Bevacizumab, Biological: Bevacizumab
Phase: Phase III
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed, Drug: Pemetrexed, Drug: Paclitaxel, Drug: Carboplatin, Biological: Bevacizumab, Biological: Bevacizumab
Phase: Phase III
Recruiting
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Biological: cetuximab, Drug: carboplatin, Drug: paclitaxel
Phase: Phase III
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Biological: cetuximab, Drug: carboplatin, Drug: paclitaxel
Phase: Phase III
Recruiting
Study of Patients With Advanced Non-Small Cell Lung Cancer
Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed, Drug: Carboplatin, Drug: Paclitaxel, Biological: Bevacizumab
Phase: Phase III
Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed, Drug: Carboplatin, Drug: Paclitaxel, Biological: Bevacizumab
Phase: Phase III
Recruiting
Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer
Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: Drug: Bevacizumab + Pemetrexed, Drug: Bevacizumab + Pemetrexed + Carboplatin
Phase: Phase III
Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: Drug: Bevacizumab + Pemetrexed, Drug: Bevacizumab + Pemetrexed + Carboplatin
Phase: Phase III
Recruiting
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: pemetrexed disodium
Phase: Phase III
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: pemetrexed disodium
Phase: Phase III
Recruiting
A Study in Second Line Non Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel, Biological: Ramucirumab, Drug: Placebo
Phase: Phase III
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel, Biological: Ramucirumab, Drug: Placebo
Phase: Phase III
Recruiting
ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Conditions: Non Squamous, Non-small-cell Lung Cancer
Interventions: Drug: Tivantinib (ARQ 197) plus erlotinib, Drug: ARQ 197 placebo plus erlotinib
Phase: Phase III
Conditions: Non Squamous, Non-small-cell Lung Cancer
Interventions: Drug: Tivantinib (ARQ 197) plus erlotinib, Drug: ARQ 197 placebo plus erlotinib
Phase: Phase III
Recruiting
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: Standard of care treatment
Phase: Phase III
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: Standard of care treatment
Phase: Phase III
Recruiting
A Study of Avastin (Bevacizumab) Versus Placebo in Combination With Carboplatin/Paclitaxel) in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: placebo, Drug: carboplatin, Drug: paclitaxel
Phase: Phase III
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: placebo, Drug: carboplatin, Drug: paclitaxel
Phase: Phase III
Recruiting
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
Conditions: Non-small-cell Lung Cancer
Interventions: Drug: ARQ 197 and Erlotinib, Drug: Placebo and Erlotinib
Phase: Phase III
Conditions: Non-small-cell Lung Cancer
Interventions: Drug: ARQ 197 and Erlotinib, Drug: Placebo and Erlotinib
Phase: Phase III
Recruiting
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab [MetMAb], Drug: erlotinib [Tarceva], Drug: Placebo
Phase: Phase III
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab [MetMAb], Drug: erlotinib [Tarceva], Drug: Placebo
Phase: Phase III
Recruiting
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: KD019, Drug: Erlotinib
Phase: Phase III
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: KD019, Drug: Erlotinib
Phase: Phase III
Recruiting
Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: erlotinib hydrochloride
Phase: Phase II
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: erlotinib hydrochloride
Phase: Phase II
Recruiting
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer
Interventions: Drug: Cisplatin, Drug: Etoposide, Drug: Placebo, Drug: Cisplatin, Drug: Etoposide, Drug: ZD6474
Phase: Phase II
Conditions: Small Cell Lung Cancer
Interventions: Drug: Cisplatin, Drug: Etoposide, Drug: Placebo, Drug: Cisplatin, Drug: Etoposide, Drug: ZD6474
Phase: Phase II
Recruiting
Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: Paclitaxel, Drug: Gemcitabine, Biological: Avastin
Phase: Phase II
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: Paclitaxel, Drug: Gemcitabine, Biological: Avastin
Phase: Phase II
Recruiting
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Drug: pemetrexed disodium, Drug: sunitinib malate
Phase: Phase II
Conditions: Lung Cancer
Interventions: Drug: pemetrexed disodium, Drug: sunitinib malate
Phase: Phase II
Recruiting
Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy
Conditions: Locally Advanced Non-Small Cell Lung Cancer, NSCLC
Interventions: Drug: Paclitaxel, Carboplatin and Bevacizumab,Erlotinib
Phase: Phase II
Conditions: Locally Advanced Non-Small Cell Lung Cancer, NSCLC
Interventions: Drug: Paclitaxel, Carboplatin and Bevacizumab,Erlotinib
Phase: Phase II
Recruiting
Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer
Conditions: Non-small-cell Lung Cancer
Interventions: Drug: Docetaxel, Drug: Bevacizumab
Phase: Phase II
Conditions: Non-small-cell Lung Cancer
Interventions: Drug: Docetaxel, Drug: Bevacizumab
Phase: Phase II
Recruiting
Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer
Conditions: Non-small-cell Lung Cancer
Interventions: Drug: Pemetrexed, Drug: Bevacizumab
Phase: Phase II
Conditions: Non-small-cell Lung Cancer
Interventions: Drug: Pemetrexed, Drug: Bevacizumab
Phase: Phase II
Recruiting
Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Carboplatin, Drug: Bevacizumab, Drug: Paclitaxel
Phase: Phase II
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Carboplatin, Drug: Bevacizumab, Drug: Paclitaxel
Phase: Phase II
Recruiting
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Drug: sorafenib tosylate
Phase: Phase II
Conditions: Lung Cancer
Interventions: Drug: sorafenib tosylate
Phase: Phase II
Recruiting
Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer
Interventions: Drug: Docetaxel, Drug: Bevacizumab
Phase: Phase II
Conditions: Small Cell Lung Cancer
Interventions: Drug: Docetaxel, Drug: Bevacizumab
Phase: Phase II
Recruiting
Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Vinorelbine, Drug: Bevacizumab
Phase: Phase II
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Vinorelbine, Drug: Bevacizumab
Phase: Phase II
Recruiting
Adjuvant Pazopanib in Stage I NSCLC
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PAZOPANIB, Drug: Placebo
Phase: Phase II, Phase III
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PAZOPANIB, Drug: Placebo
Phase: Phase II, Phase III
Recruiting
Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Biological: aflibercept, Drug: topotecan hydrochloride
Phase: Phase II
Conditions: Lung Cancer
Interventions: Biological: aflibercept, Drug: topotecan hydrochloride
Phase: Phase II
Recruiting
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Conditions: Non-Small Cell Lung Cancer
Interventions: Biological: Imprime PGG® Injection, Biological: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin
Phase: Phase II
Conditions: Non-Small Cell Lung Cancer
Interventions: Biological: Imprime PGG® Injection, Biological: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin
Phase: Phase II
Recruiting
Trial of Poor Performance Status Patients (ToPPS)
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed, Drug: Bevacizumab, Drug: Carboplatin
Phase: Phase II
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed, Drug: Bevacizumab, Drug: Carboplatin
Phase: Phase II
Recruiting
A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Conditions: Non-Small Cell Lung Cancer
Interventions: Biological: IMC-3G3, Drug: Paclitaxel, Drug: carboplatin
Phase: Phase II
Conditions: Non-Small Cell Lung Cancer
Interventions: Biological: IMC-3G3, Drug: Paclitaxel, Drug: carboplatin
Phase: Phase II
Recruiting
Bevacizumab in Extensive Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer
Interventions: Drug: Standard Chemotherapy (PCDE or PE), Drug: Experimental Treatment (PCDE or PE + bevacizumab), Drug: Prerandomization Chemotherapy (PCDE or PE)
Phase: Phase II, Phase III
Conditions: Small Cell Lung Cancer
Interventions: Drug: Standard Chemotherapy (PCDE or PE), Drug: Experimental Treatment (PCDE or PE + bevacizumab), Drug: Prerandomization Chemotherapy (PCDE or PE)
Phase: Phase II, Phase III
Recruiting
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
Conditions: Advanced Non-small Cell Lung Cancer, Postmenopausal Women
Interventions: Drug: fulvestrant (Faslodex), Drug: anastrozole (Arimidex), Drug: Bevacizumab (Avastin), Drug: Best standard of care
Phase: Phase II
Conditions: Advanced Non-small Cell Lung Cancer, Postmenopausal Women
Interventions: Drug: fulvestrant (Faslodex), Drug: anastrozole (Arimidex), Drug: Bevacizumab (Avastin), Drug: Best standard of care
Phase: Phase II
Recruiting
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Conditions: Solid Tumors, Cancer
Interventions: Drug: XL184, Drug: Placebo, Drug: XL184, Drug: XL184
Phase: Phase II
Conditions: Solid Tumors, Cancer
Interventions: Drug: XL184, Drug: Placebo, Drug: XL184, Drug: XL184
Phase: Phase II
Recruiting
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Biological: cixutumumab, Drug: carboplatin, Drug: paclitaxel
Phase: Phase II
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Biological: cixutumumab, Drug: carboplatin, Drug: paclitaxel
Phase: Phase II
Recruiting
NGR-hTNF Administered in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: NGR-hTNF, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed
Phase: Phase II
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: NGR-hTNF, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed
Phase: Phase II
Recruiting
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed, Cisplatin, Bevacizumab
Phase: Phase II
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed, Cisplatin, Bevacizumab
Phase: Phase II
Recruiting
Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: Suramin + Docetaxel + Carboplatin, Drug: Placebo + Docetaxel + Carboplatin
Phase: Phase II
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: Suramin + Docetaxel + Carboplatin, Drug: Placebo + Docetaxel + Carboplatin
Phase: Phase II
Recruiting
Molecular Imaging With Erlotinib and Bevacizumab
Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Drug: Erlotinib, Bevacizumab, Drug: Fluoro-D-glucose, Drug: Fluoro-L-thymidine, Drug: Gadolinium-DPTA
Phase: Phase II
Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Drug: Erlotinib, Bevacizumab, Drug: Fluoro-D-glucose, Drug: Fluoro-L-thymidine, Drug: Gadolinium-DPTA
Phase: Phase II
Recruiting
GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Pazopanib (GW786034)
Phase: Phase II
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Pazopanib (GW786034)
Phase: Phase II
Recruiting
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: Drug: ixabepilone, Drug: bevacizumab
Phase: Phase II
Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: Drug: ixabepilone, Drug: bevacizumab
Phase: Phase II
Recruiting
A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: gemcitabine, Drug: gemcitabine, Drug: cisplatin
Phase: Phase II
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: gemcitabine, Drug: gemcitabine, Drug: cisplatin
Phase: Phase II
Recruiting
Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
Conditions: Advanced Non-small Cell Lung Cancer
Interventions: Drug: CS-7017, Drug: erlotinib
Phase: Phase II
Conditions: Advanced Non-small Cell Lung Cancer
Interventions: Drug: CS-7017, Drug: erlotinib
Phase: Phase II
Recruiting
Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: cisplatin, Drug: erlotinib hydrochloride, Drug: pemetrexed disodium, Genetic: gene expression analysis, Genetic: mutation analysis, Other: laboratory biomarker analysis, Other: pharmacogenomic studies
Phase: Phase II
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: cisplatin, Drug: erlotinib hydrochloride, Drug: pemetrexed disodium, Genetic: gene expression analysis, Genetic: mutation analysis, Other: laboratory biomarker analysis, Other: pharmacogenomic studies
Phase: Phase II
Recruiting
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy
Conditions: Non-small-cell Lung Cancer
Interventions: Drug: AUY922
Phase: Phase II
Conditions: Non-small-cell Lung Cancer
Interventions: Drug: AUY922
Phase: Phase II
Recruiting
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: imetelstat, Drug: Bevacizumab
Phase: Phase II
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: imetelstat, Drug: Bevacizumab
Phase: Phase II
Recruiting
Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
Conditions: Small Cell Lung Cancer
Interventions: Drug: Sorafenib
Phase: Phase II
Conditions: Small Cell Lung Cancer
Interventions: Drug: Sorafenib
Phase: Phase II
Recruiting
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab), Drug: Pemetrexed, Drug: Carboplatin (AUC 6), Drug: Cisplatin, Drug: Gemcitabine, Drug: Carboplatin (AUC 5)
Phase: Phase II
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab), Drug: Pemetrexed, Drug: Carboplatin (AUC 6), Drug: Cisplatin, Drug: Gemcitabine, Drug: Carboplatin (AUC 5)
Phase: Phase II
Recruiting
Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: carboplatin paclitaxel bevacizumab, Drug: Standard treatment plus nitroglycerin
Phase: Phase II
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: carboplatin paclitaxel bevacizumab, Drug: Standard treatment plus nitroglycerin
Phase: Phase II
Recruiting
Stage IIIB/IV Non-Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Pazopanib plus Paclitaxel
Phase: Phase II
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Pazopanib plus Paclitaxel
Phase: Phase II
Recruiting
RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy
Conditions: Lung Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097, Genetic: fluorescence in situ hybridization, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Other: pharmacogenomic studies, Other: pharmacological study
Phase: Phase II
Conditions: Lung Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097, Genetic: fluorescence in situ hybridization, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Other: pharmacogenomic studies, Other: pharmacological study
Phase: Phase II
Recruiting
Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy
Conditions: Lung Cancer
Interventions: Drug: pazopanib hydrochloride, Other: laboratory biomarker analysis, Other: pharmacogenomic studies, Other: pharmacological study, Procedure: quality-of-life assessment
Phase: Phase II, Phase III
Conditions: Lung Cancer
Interventions: Drug: pazopanib hydrochloride, Other: laboratory biomarker analysis, Other: pharmacogenomic studies, Other: pharmacological study, Procedure: quality-of-life assessment
Phase: Phase II, Phase III
Recruiting
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Conditions: Non Small Cell Lung Carcinoma
Interventions: Drug: AZD6244, Drug: Erlotinib, Drug: AZD6244 + Erlotinib
Phase: Phase II
Conditions: Non Small Cell Lung Carcinoma
Interventions: Drug: AZD6244, Drug: Erlotinib, Drug: AZD6244 + Erlotinib
Phase: Phase II
Recruiting
Selumetinib and Erlotinib Hydrochloride in Patients With Advanced Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Drug: erlotinib hydrochloride, Drug: selumetinib
Phase: Phase II
Conditions: Lung Cancer
Interventions: Drug: erlotinib hydrochloride, Drug: selumetinib
Phase: Phase II
Recruiting
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study
Conditions: Lung Cancer
Interventions: Drug: Erlotinib, Drug: AZD6244, Drug: MK-2206, Drug: Sorafenib, Drug: Erlotinib, Drug: MK-2206
Phase: Phase II
Conditions: Lung Cancer
Interventions: Drug: Erlotinib, Drug: AZD6244, Drug: MK-2206, Drug: Sorafenib, Drug: Erlotinib, Drug: MK-2206
Phase: Phase II
Recruiting
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Conditions: Lung Cancer
Interventions: Drug: Pazopanib
Phase: Phase II
Conditions: Lung Cancer
Interventions: Drug: Pazopanib
Phase: Phase II
Recruiting
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Drug: Carboplatin, Drug: Pemetrexed, Drug: Bevacizumab, Drug: Cetuximab, Drug: Cixutumumab
Phase: Phase II
Conditions: Lung Cancer
Interventions: Drug: Carboplatin, Drug: Pemetrexed, Drug: Bevacizumab, Drug: Cetuximab, Drug: Cixutumumab
Phase: Phase II
Recruiting
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Conditions: Lung Cancer
Interventions: Drug: Akt inhibitor MK2206, Drug: erlotinib hydrochloride, Other: laboratory biomarker analysis, Other: pharmacological study
Phase: Phase II
Conditions: Lung Cancer
Interventions: Drug: Akt inhibitor MK2206, Drug: erlotinib hydrochloride, Other: laboratory biomarker analysis, Other: pharmacological study
Phase: Phase II
Recruiting
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: BKM120 or Docetaxel, Drug: BKM120 or Docetaxel or Pemetrexed
Phase: Phase II
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: BKM120 or Docetaxel, Drug: BKM120 or Docetaxel or Pemetrexed
Phase: Phase II
Recruiting
Investigation of Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: SB injection
Phase: Phase II
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: SB injection
Phase: Phase II
Recruiting
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
Interventions: Drug: AZD, Drug: MK-2206, Drug: Lapatinib, Drug: Erlotinib, Drug: Sunitinib, Procedure: Molecular Profiling
Phase: Phase II
Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
Interventions: Drug: AZD, Drug: MK-2206, Drug: Lapatinib, Drug: Erlotinib, Drug: Sunitinib, Procedure: Molecular Profiling
Phase: Phase II
Recruiting
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
Conditions: Lung Cancer, Small Cell
Interventions: Drug: pazopanib, Drug: pemetrexed
Phase: Phase II
Conditions: Lung Cancer, Small Cell
Interventions: Drug: pazopanib, Drug: pemetrexed
Phase: Phase II
Recruiting
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
Conditions: Carcinoma, Large Cell, Neuroendocrine Tumors
Interventions: Drug: RAD001 + paclitaxel/carboplatin
Phase: Phase II
Conditions: Carcinoma, Large Cell, Neuroendocrine Tumors
Interventions: Drug: RAD001 + paclitaxel/carboplatin
Phase: Phase II
Recruiting
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: carboplatin, Drug: erlotinib hydrochloride, Drug: pemetrexed disodium
Phase: Phase II
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: carboplatin, Drug: erlotinib hydrochloride, Drug: pemetrexed disodium
Phase: Phase II
Recruiting
Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab, Drug: carboplatin, Drug: MEGF0444A, Drug: paclitaxel, Drug: placebo
Phase: Phase II
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab, Drug: carboplatin, Drug: MEGF0444A, Drug: paclitaxel, Drug: placebo
Phase: Phase II
Recruiting
Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)
Conditions: NSCLC
Interventions: Drug: Bevacizumab, Drug: Cisplatin, Drug: Docetaxel
Phase: Phase II
Conditions: NSCLC
Interventions: Drug: Bevacizumab, Drug: Cisplatin, Drug: Docetaxel
Phase: Phase II
Recruiting
Erlotinib Plus ARQ 197 Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions: Metastatic Non-Small Cell Lung Cancer
Interventions: Drug: ARQ 197 plus erlotinib, Drug: Pemetrexed, docetaxel or gemcitabine
Phase: Phase II
Conditions: Metastatic Non-Small Cell Lung Cancer
Interventions: Drug: ARQ 197 plus erlotinib, Drug: Pemetrexed, docetaxel or gemcitabine
Phase: Phase II
Recruiting
A Study of Axitinib in Advanced Carcinoid Tumors
Conditions: Carcinoid Tumor
Interventions: Drug: Axitinib
Phase: Phase II
Conditions: Carcinoid Tumor
Interventions: Drug: Axitinib
Phase: Phase II
Recruiting
Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941, Drug: carboplatin, Drug: paclitaxel, Drug: bevacizumab, Drug: Placebo
Phase: Phase II
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941, Drug: carboplatin, Drug: paclitaxel, Drug: bevacizumab, Drug: Placebo
Phase: Phase II
Recruiting
Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: pegylated endostatin and Paclitaxel-Carboplatin, Drug: Placebo and Paclitaxel-Carboplatin
Phase: Phase II
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: pegylated endostatin and Paclitaxel-Carboplatin, Drug: Placebo and Paclitaxel-Carboplatin
Phase: Phase II
Not yet recruiting
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer, Small Cell Lung Cancer Recurrent
Interventions: Drug: BIBF 1120
Phase: Phase II
Conditions: Small Cell Lung Cancer, Small Cell Lung Cancer Recurrent
Interventions: Drug: BIBF 1120
Phase: Phase II
Not yet recruiting
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: RO5490258, Drug: bevacizumab [Avastin], Drug: pemetrexed, Drug: Placebo, Drug: cisplatin/carboplatin, Drug: paclitaxel
Phase: Phase II
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: RO5490258, Drug: bevacizumab [Avastin], Drug: pemetrexed, Drug: Placebo, Drug: cisplatin/carboplatin, Drug: paclitaxel
Phase: Phase II
Not yet recruiting
BKM120 in Cancers With PIK3CA Activating Mutations
Conditions: Lung Cancer, Breast Cancer, Colorectal Cancer, Cholangiocarcinoma, Solid Tumors
Interventions: Drug: BKM120
Phase: Phase II
Conditions: Lung Cancer, Breast Cancer, Colorectal Cancer, Cholangiocarcinoma, Solid Tumors
Interventions: Drug: BKM120
Phase: Phase II
Not yet recruiting
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab, Drug: Placebo, Drug: paclitaxel, Drug: cisplatin/carboplatin
Phase: Phase II
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab, Drug: Placebo, Drug: paclitaxel, Drug: cisplatin/carboplatin
Phase: Phase II
Not yet recruiting
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: Lenvatinib (E7080)
Phase: Phase II
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: Lenvatinib (E7080)
Phase: Phase II
Not yet recruiting
Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations
Conditions: Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib, Biological: bevacizumab, Other: laboratory biomarker analysis
Phase: Phase II
Conditions: Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib, Biological: bevacizumab, Other: laboratory biomarker analysis
Phase: Phase II
Clinical Trial Data provided by http://www.clinicaltrials.gov.